Drug intelligence / Profile preview

Levellor

Development stage: Unknown
Lead developer: InsuLife
Modality: Recombinant Proteins and Enzymes
Administration: Transdermal

Overview

Levellor is a transdermal, spray-on formulation of recombinant human insulin developed by Transdermal Delivery Solutions Corp (TDSC) and later acquired by InsuLife. It utilizes the proprietary HypoSpray technology, which is designed to alter the lipid layers of the skin to facilitate the systemic delivery of insulin without the use of needles. The system is intended to provide dose-dependent glucose control for the treatment of diabetes mellitus. Clinical development has included a Phase 2 randomized, dose-ranging study evaluating its glucose-lowering effects and tolerability in healthy adult volunteers.

Brand names: Levellor
Other names: transdermal human insulinHypoSpray insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on Levellor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Levellor.

Explore the full profile